DENVER, March 11, 2019 /PRNewswire/ -- Helix TCS, Inc. (OTCQB: HLIX) (the "Company"), through its leading seed to sale and cannabis point of sale subsidiary, BioTrackTHC, has been awarded a 2-year contract extension with the State of Delaware to continue providing the state's medical cannabis traceability system through April 30, 2021. BioTrackTHC was awarded the Delaware traceability contract in May of 2017 and currently operates 9 government cannabis tracking systems across 7 states, Puerto Rico, and the city of Arcata, California.
"As more states and countries launch medical cannabis programs, and the real, beneficial outcomes of those programs are understood, medical programs often then evolve into adult-use programs, and Helix TCS is ideally positioned to support this transition to ensure that it is safe, transparent, and efficient," said Zachary L. Venegas, Executive Chairman and CEO of Helix TCS, Inc. "It has been our pleasure to support the State of Delaware's Department of Health and Delaware's medical cannabis industry, and we look forward to continuing to support the program and provide critical infrastructure as it evolves."
About Helix TCS, Inc. BioTrackTHC is a wholly-owned subsidiary of Helix TCS, Inc. Helix TCS, Inc. (OTCQB: HLIX) is a leading provider of critical infrastructure services, helping owners and operators of licensed cannabis businesses stay competitive and compliant while mitigating risk. Through its proprietary technology suite and security services, Helix TCS provides comprehensive supply chain management, compliance tools, and asset protection for any license type in any regulated cannabis market. Helix TCS's products reach over 2,000 customer locations in 33 states and 6 countries and has processed over $18 billion in cannabis sales. For more information on BioTrackTHC, visit www.biotrack.com. For more information on Helix TCS and to sign up for investor updates, visit us at www.helixtcs.com.
Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to fund our operations and pay any outstanding debt; fluctuations in our financial results; general economic risks; the volatile nature of the market for our products and services and other factors that could impact our anticipated growth; our ability to manage our growth; changes in laws and regulations regarding the cannabis industry and service providers in the cannabis industry; reliance on key personnel; our ability to compete effectively; security and other risks associated with our business; intellectual property risks; and other risk factors set forth from time to time in our SEC filings. Helix TCS assumes no obligation and does not intend to update these forward-looking statements, except as required by law.